Skip to main content

Advertisement

Fig. 1 (abstract P18). | Journal of Pharmaceutical Policy and Practice

Fig. 1 (abstract P18).

From: Abstracts from the 4th International PPRI Conference 2019: Medicines access challenge – The value of pricing and reimbursement policies

Fig. 1 (abstract P18).

Ex-factory prices of at least 2 pharmaceutical presentations of the same active ingredient for 27 EU Member States, 2017 (average price of each presentation = 100). Notes: The average price of each presentation defined as an index (= 100). The box corresponds to the area in which the middle 50% of the data are located (interquartile distance). The black line describes the location of the median. The dashed whiskers are limited to 1.5 times the length of the interquartile range. The circles stand for statistical outliers. The analysis was run for all 27 European Union Member States (all but Malta). Included presentations: Ada = adalimumab 40 mg, 0.8 ml, injection for solution, 2 pre-filled syringes (A), adalimumab 40 mg, 0.8 ml, injection for solution, 2 pre-filled pens (B); Api = apixaban 2.5 mg, 60 f/c tablets (A), apixaban 5 mg, 60 f/c tablets (B); Bev = bevacizumab 100 mg / 4 ml concentrate to produce a solution for infusion, 1 vial (A), bevacizumab 400 mg / 16 ml concentrate to produce a solution for infusion, 1 vial (B); Car = carfilzomib 60 mg / 30 ml powder for solution for infusion, 1 vial (A), carfilzomib 10 mg / 5 ml powder for solution for infusion, 1 vial (B), carfilzomib 30 mg / 15 ml powder for solution for infusion, 1 vial (C); Cet = cetuximab 100 mg / 20 ml solution for infusion, 1 vial (A), cetuximab 500 mg / 100 ml solution for infusion, 1 vial (B); Dab = dabigatran etexilate 110 mg, 30 hard capsules (A), dabigatran etexilate 150 mg, 30 hard capsules (B), Dar = daratumumab 100mg / 5 ml concentrate to produce a solution for infusion, 1 vial (A), daratumumab 400mg / 20 ml concentrate to produce a solution for infusion, 1 vial (B); Den = denosumab 60 mg / 1 ml solution for injection, 1 pre-filled syringe (A), denosumab 120 mg / 1.7 ml solution for injection, 1 vial (B); Dex = dexmedetomidine 200 mcg / 2 ml concentrate to produce a solution for infusion, 5 ampoules (A), dexmedetomidine 200 mcg / 2 ml concentrate to produce a solution for infusion, 25 ampoules (B); Eta = etanercept 50 mg / 1 ml solution for injection, 4 pre-filled syringes (A), etanercept 50 mg / 1 ml solution for injection, 4 pre-filled syringes (B); Gol = golimumab 50 mg / 0.5 ml solution for injection, 1 pre-filled pen (A), golimumab 50 mg / 0.5 ml solution for injection, 1 pre-filled syringe (B); Ipi = ipilimumab 50 mg / 10ml concentrate to produce a solution for infusion, 1 vial (A), ipilimumab 200 mg / 40 ml concentrate to produce a solution for infusion, 1 vial (B); Len = lenalidomid 10 mg, 21 hard capsules (A), lenalidomid 15 mg, 21 hard capsules (B); Mic = micafungin 50 mg / 10 ml powder for a concentrate to produce a solution for infusion, 1 vial (A), micafungin 100 mg / 10 ml powder for a concentrate to produce a solution for infusion, 1 vial (B); Niv = nivolumab 40 mg / 4 ml concentrate to produce a solution for infusion, 1 vial (A), nivolumab 100 mg / 10 ml concentrate to produce a solution for infusion, 1 vial (B); Pem = pembrolizumab 50 mg / 2 ml powder for a concentrate to produce a solution for infusion, 1 vial (A), pembrolizumab 100 mg / 4 ml powder for a concentrate to produce a solution for infusion, 1 vial (B); Pos = posaconazole 100 mg, 24 enteric tablets (A), posaconazole 100 mg, 96 enteric tablets (B), Riv = rivaroxaban 20 mg, 30 film-coated tablets (A), rivaroxaban 20 mg, 30 film-coated tablets (B); Ros = rosuvastatin 10 mg, 30 film-coated tablets (A), rosuvastatin 20 mg, 30 film-coated tablets (B); Tio = tiotropium bromid 18 mcg inhalation powder, 30 capsules (A), tiotropium bromid 2.5 mcg inhalation solution, 1 inhaler (B); Tra = trastuzumab 150 mg / 7.2 ml powder for a concentrate to produce a solution for infusion, 1 vial (A), trastuzumab 120 mg / 5 ml a solution for injection, 1 vial (B); TrEm = trastuzumab emtansine 100 mg / 5 ml powder for a concentrate to produce a solution for infusion, 1 vial (A), trastuzumab emtansine 160 mg / 8 ml powder for a concentrate to produce a solution for infusion, 1 vial (B)

Back to article page